Abstract：
Resistant starches (RSs) have been advocated as a dietary supplement to address microbiota dysbiosis. They are postulated to act through the production of SCFAs. Their clinical tolerability and effect on SCFA production has not been systematically evaluated.
We conducted a systematic review of RS supplementation as an intervention in adults (healthy individuals and persons with medical conditions) participating in randomized controlled trials. The primary outcome was tolerability of RS supplementation, the secondary outcome was SCFA production.
MEDLINE, Embase, and the Cochrane Central Register were searched. Articles were screened, and data extracted, independently and in duplicate.
A total of 39 trials met eligibility criteria, including a total of 2263 patients. Twenty-seven (69%) studies evaluated the impact of RS supplementation in healthy subjects whereas 12 (31%) studies included individuals with an underlying medical condition (e.g., obesity, prediabetes). Type 2 RS was most frequently investigated (29 studies). Of 12 studies performed in subjects with health conditions, 11 reported on tolerability. All studies showed that RS supplementation was tolerated; 9 of these studies used type 2 RS with doses of 20-40 g/d for >4 wk. Of 27 studies performed in healthy subjects, 20 reported on tolerability. In 14 studies, RS supplementation was tolerated, and the majority used type 2 RS with a dose between 20 and 40 g/d. Twenty-one (78%) studies reporting SCFAs used type 2 RS with a dose of 20-40 g/d for 1-4 wk. In 16 of 23 studies (70%), SCFA production was increased, in 7 studies there was no change in SCFA concentration before and after RS supplementation, and in 1 study SCFA concentration decreased.
Available evidence suggests that RS supplementation is tolerated in both healthy subjects and in those with an underlying medical condition. In addition, SCFA production was increased in most of the studies.
We conducted a systematic review of RS supplementation as an intervention in adults (healthy individuals and persons with medical conditions) participating in randomized controlled trials. The primary outcome was tolerability of RS supplementation, the secondary outcome was SCFA production.
MEDLINE, Embase, and the Cochrane Central Register were searched. Articles were screened, and data extracted, independently and in duplicate.
A total of 39 trials met eligibility criteria, including a total of 2263 patients. Twenty-seven (69%) studies evaluated the impact of RS supplementation in healthy subjects whereas 12 (31%) studies included individuals with an underlying medical condition (e.g., obesity, prediabetes). Type 2 RS was most frequently investigated (29 studies). Of 12 studies performed in subjects with health conditions, 11 reported on tolerability. All studies showed that RS supplementation was tolerated; 9 of these studies used type 2 RS with doses of 20-40 g/d for >4 wk. Of 27 studies performed in healthy subjects, 20 reported on tolerability. In 14 studies, RS supplementation was tolerated, and the majority used type 2 RS with a dose between 20 and 40 g/d. Twenty-one (78%) studies reporting SCFAs used type 2 RS with a dose of 20-40 g/d for 1-4 wk. In 16 of 23 studies (70%), SCFA production was increased, in 7 studies there was no change in SCFA concentration before and after RS supplementation, and in 1 study SCFA concentration decreased.
Available evidence suggests that RS supplementation is tolerated in both healthy subjects and in those with an underlying medical condition. In addition, SCFA production was increased in most of the studies.
摘要：
抗性淀粉(RS)已被提倡作为解决微生物群生态失调的膳食补充剂。假定他们通过生产SCFA来采取行动。尚未系统地评估其临床耐受性和对SCFA产生的影响。
我们对参与随机对照试验的成年人（健康个体和有医疗条件的人）补充RS作为干预措施进行了系统评价。主要结果是RS补充的耐受性，次要结局是SCFA产生.
MEDLINE,Embase,搜查了Cochrane中央登记册.文章进行了筛选，和提取的数据，独立和一式两份。
共有39项试验符合资格标准，共2263名患者。27项（69％）研究评估了RS补充对健康受试者的影响，而12项（31％）研究包括具有潜在医疗状况的个体（例如，肥胖，糖尿病前期)。2型RS是最常见的研究（29项研究）。在有健康状况的受试者中进行的12项研究中，11报告了耐受性。所有研究表明RS补充是耐受的；这些研究中有9项使用2型RS，剂量为20-40g/d，持续>4周。在健康受试者中进行的27项研究中，20报道了耐受性。在14项研究中，RS补充是耐受的，大多数使用2型RS，剂量在20至40g/d之间。21项（78％）研究报告SCFA使用2型RS，剂量为20-40g/d，持续1-4周。在23项研究中的16项（70%），SCFA产量增加，在7项研究中，补充RS前后SCFA浓度没有变化，1研究中SCFA浓度降低。
现有证据表明，RS补充剂在健康受试者和具有潜在医学状况的受试者中均可耐受。此外,在大多数研究中SCFA产量增加。
我们对参与随机对照试验的成年人（健康个体和有医疗条件的人）补充RS作为干预措施进行了系统评价。
MEDLINE,
共有39项试验符合资格标准，
现有证据表明，RS补充剂在健康受试者和具有潜在医学状况的受试者中均可耐受。
